KR20000070035A - 치료를 위한 항ｃｄ40ｌ 화합물의 투여 방법 - Google Patents

치료를 위한 항ｃｄ40ｌ 화합물의 투여 방법 Download PDF

Info

Publication number
KR20000070035A
KR20000070035A KR1019997006254A KR19997006254A KR20000070035A KR 20000070035 A KR20000070035 A KR 20000070035A KR 1019997006254 A KR1019997006254 A KR 1019997006254A KR 19997006254 A KR19997006254 A KR 19997006254A KR 20000070035 A KR20000070035 A KR 20000070035A
Authority
KR
South Korea
Prior art keywords
weeks
patient
cd40l
therapeutically effective
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019997006254A
Other languages
English (en)
Korean (ko)
Inventor
칼레드수잔엘
토마스데이비드더블유
Original Assignee
아스트루 마이클 제이
바이오겐, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트루 마이클 제이, 바이오겐, 인코포레이티드 filed Critical 아스트루 마이클 제이
Publication of KR20000070035A publication Critical patent/KR20000070035A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1019997006254A 1997-01-10 1998-01-09 치료를 위한 항ｃｄ40ｌ 화합물의 투여 방법 Ceased KR20000070035A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3467297P 1997-01-10 1997-01-10
US60/034,672 1997-01-10
US4015497P 1997-03-07 1997-03-07
US60/040,154 1997-03-07

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020057013115A Division KR100632846B1 (ko) 1997-01-10 1998-01-09 치료를 위한 항ｃｄ40ｌ 화합물의 투여 방법

Publications (1)

Publication Number Publication Date
KR20000070035A true KR20000070035A (ko) 2000-11-25

Family

ID=26711241

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1019997006254A Ceased KR20000070035A (ko) 1997-01-10 1998-01-09 치료를 위한 항ｃｄ40ｌ 화합물의 투여 방법
KR1020057013115A Expired - Fee Related KR100632846B1 (ko) 1997-01-10 1998-01-09 치료를 위한 항ｃｄ40ｌ 화합물의 투여 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020057013115A Expired - Fee Related KR100632846B1 (ko) 1997-01-10 1998-01-09 치료를 위한 항ｃｄ40ｌ 화합물의 투여 방법

Country Status (20)

Country Link
US (2) US20020071840A1 (https=)
EP (1) EP0966302B1 (https=)
JP (1) JP2001508450A (https=)
KR (2) KR20000070035A (https=)
CN (1) CN1248921A (https=)
AT (1) ATE356634T1 (https=)
AU (1) AU721697B2 (https=)
BR (1) BR9807471A (https=)
CA (1) CA2277223A1 (https=)
CZ (1) CZ244399A3 (https=)
DE (1) DE69837322T2 (https=)
EA (1) EA001426B1 (https=)
EE (1) EE9900275A (https=)
IL (1) IL130785A0 (https=)
IS (1) IS5101A (https=)
NO (1) NO993275L (https=)
NZ (1) NZ337073A (https=)
PL (1) PL193966B1 (https=)
TR (1) TR199902192T2 (https=)
WO (1) WO1998030241A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
BR9809641A (pt) * 1997-05-17 2000-07-11 Biogen Inc Uso de um interruptor de ligação cd40:cd154 para evitar respostas imunes inadaptadas, particularmente rejeição a enxerto
CN1261285A (zh) * 1997-06-20 2000-07-26 拜奥根有限公司 治疗性蛋白抑制剂综合症的cd154阻断治疗
NZ511034A (en) * 1998-09-21 2004-03-26 American Nat Red Cross Methods of downmodulating the immune response to therapeutic proteins
WO2000072882A1 (fr) * 1999-06-01 2000-12-07 Eisai Co., Ltd. Agents prophylactiques du purpura thrombocytopenique idiopathique
GB9927757D0 (en) * 1999-11-25 2000-01-26 Kennedy Rheumatology Inst Treatment of autoimmune diseases
WO2001066141A1 (fr) * 2000-03-06 2001-09-13 Eisai Co., Ltd. Agents therapeutiques et prophylactiques diriges contre le syndrome des antiphospholipides
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
CA2781858C (en) 2000-05-12 2015-03-31 Genzyme Corporation Modulators of tnf-.alpha. signaling
JP3785508B2 (ja) * 2002-04-15 2006-06-14 学校法人慶應義塾 遺伝子治療における免疫応答を解析できる実験モデルマウス
ATE520400T1 (de) * 2002-11-21 2011-09-15 Genzyme Corp Kombination von einem diamidderivat und immunsuppressiva zur unterdrückung der transplantatabstossung
EP2367849B1 (en) 2008-12-05 2017-11-01 ALS Therapy Development Institute Method for the treatment of neurodegenerative diseases
WO2025117849A1 (en) 2023-11-28 2025-06-05 Eledon Pharmaceuticals, Inc. Methods and compositions for prevention of transplant rejection
WO2025235683A1 (en) 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Methods and compositions for prevention of transplant rejection

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5961974A (en) * 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
ZA946765B (en) * 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
ES2143553T3 (es) * 1993-09-02 2000-05-16 Dartmouth College Anticuerpos anti-gp39 y sus utilizaciones.
NZ273208A (en) * 1993-09-02 2000-12-22 Dartmouth College Suppressing a humoral immune response against a thymus dependant (TD) antigen
ES2222463T3 (es) * 1993-12-23 2005-02-01 Immunex Corporation Uso de anticuerpos monoclonales o ligandos oligomericos solubles en la fabricacion de un medicamento para la prevencion o tratamiento de trastornos neoplasicos.
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
EP0892643B2 (en) * 1996-03-20 2009-09-02 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith

Also Published As

Publication number Publication date
US20050158314A1 (en) 2005-07-21
CA2277223A1 (en) 1998-07-16
KR20050088494A (ko) 2005-09-06
CZ244399A3 (cs) 1999-10-13
CN1248921A (zh) 2000-03-29
PL334500A1 (en) 2000-02-28
EE9900275A (et) 2000-02-15
KR100632846B1 (ko) 2006-10-16
WO1998030241A1 (en) 1998-07-16
AU721697B2 (en) 2000-07-13
DE69837322D1 (de) 2007-04-26
EA001426B1 (ru) 2001-02-26
BR9807471A (pt) 2000-03-21
DE69837322T2 (de) 2007-11-22
JP2001508450A (ja) 2001-06-26
EP0966302B1 (en) 2007-03-14
AU5735398A (en) 1998-08-03
US20020071840A1 (en) 2002-06-13
HK1024424A1 (en) 2000-10-13
PL193966B1 (pl) 2007-04-30
TR199902192T2 (xx) 1999-12-21
EP0966302A1 (en) 1999-12-29
EA199900633A1 (ru) 2000-02-28
IS5101A (is) 1999-06-30
NZ337073A (en) 2001-01-26
IL130785A0 (en) 2001-01-28
NO993275D0 (no) 1999-07-01
ATE356634T1 (de) 2007-04-15
NO993275L (no) 1999-09-09

Similar Documents

Publication Publication Date Title
KR100618081B1 (ko) 항 ｃｄ40ｌ 화합물을 포함하는 신염성 루푸스의 치료용약제
KR100632846B1 (ko) 치료를 위한 항ｃｄ40ｌ 화합물의 투여 방법
KR100575069B1 (ko) 역적응성 면역 반응, 특히 이식 거부반응을 예방하기 위한ｃｄ40:ｃｄ154 결합 저해제의 용도
DE69637131T2 (de) Humanisierte antikörper gegen humanes gp39, zusammensetzungen die diese enthalten und deren therapeutische verwendungen
WO1998030240A9 (en) Treatment of lupus nephritis with anti-cd40l compounds
KR101800467B1 (ko) 루푸스 치료 방법 및 조성물
WO1998039026A2 (en) Methods of therapeutic administration of anti-cd40l compounds
KR100567998B1 (ko) 치료용 단백질 저해제 증후군에 대한 ｃｄ154 차단 요법
EP1824885A1 (en) Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
HK1024424B (en) Methods of therapeutic administration of anti-cd40l compounds
HK1062829A (en) Treatment of lupus nephritis with anti-cd4ol compounds
AU2920002A (en) Treatment of lupus nephritis with Anti-CD40L compounds
Sorbera et al. Alefacept

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19990709

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20030109

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20050228

Patent event code: PE09021S01D

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20050715

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20051206

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20050228

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I